JP2016536568A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016536568A5 JP2016536568A5 JP2016515521A JP2016515521A JP2016536568A5 JP 2016536568 A5 JP2016536568 A5 JP 2016536568A5 JP 2016515521 A JP2016515521 A JP 2016515521A JP 2016515521 A JP2016515521 A JP 2016515521A JP 2016536568 A5 JP2016536568 A5 JP 2016536568A5
- Authority
- JP
- Japan
- Prior art keywords
- autoantibodies
- ovarian cancer
- autoantibody
- subject
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2013903595A AU2013903595A0 (en) | 2013-09-18 | Autoantibody biomarkers of ovarian cancer | |
| AU2013903595 | 2013-09-18 | ||
| PCT/AU2014/000925 WO2015039175A1 (en) | 2013-09-18 | 2014-09-18 | Autoantibody biomarkers of ovarian cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016536568A JP2016536568A (ja) | 2016-11-24 |
| JP2016536568A5 true JP2016536568A5 (https=) | 2017-10-26 |
| JP6588893B2 JP6588893B2 (ja) | 2019-10-09 |
Family
ID=52687999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016515521A Active JP6588893B2 (ja) | 2013-09-18 | 2014-09-18 | 卵巣がんの自己抗体バイオマーカー |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20160291025A1 (https=) |
| EP (1) | EP3047277B1 (https=) |
| JP (1) | JP6588893B2 (https=) |
| CN (1) | CN105745543B (https=) |
| AU (1) | AU2014324080B2 (https=) |
| CA (1) | CA2924600A1 (https=) |
| WO (1) | WO2015039175A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107056888A (zh) * | 2017-03-01 | 2017-08-18 | 中山大学肿瘤防治中心 | Atp1a1靶向多肽及应用 |
| CN109116024B (zh) * | 2018-06-14 | 2021-04-23 | 郑州大学第一附属医院 | 一种肺癌标志物抗-actr3自身抗体及其应用 |
| GB201813137D0 (en) | 2018-08-10 | 2018-09-26 | Medannex Ltd | Cancer treatment with an antibody |
| CN109182260A (zh) * | 2018-09-11 | 2019-01-11 | 邵勇 | 一种体外培养胎膜间充质干细胞的方法 |
| CN109480771B (zh) * | 2018-10-17 | 2021-09-07 | 江西惠肽生物科技有限公司 | 一种卵巢肿块良恶的确定方法及确定装置 |
| ES2952139T3 (es) * | 2019-03-01 | 2023-10-27 | Advanced Marker Discovery S L | Firma proteica para el diagnóstico de cáncer colorrectal y/o etapa precancerosa del mismo |
| US20240186001A1 (en) * | 2019-10-16 | 2024-06-06 | Icahn School Of Medicine At Mount Sinai | Systems and methods for detecting a disease condition |
| US12152280B2 (en) | 2021-09-20 | 2024-11-26 | Droplet Biosciences, Inc. | Drain fluid for diagnostics |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000054805A1 (en) * | 1999-03-15 | 2000-09-21 | University Of Maryland, Baltimore | SURFACE LOCALIZED COLLIGIN/HsP47 IN CARCINOMA CELLS |
| US6645465B2 (en) * | 1999-08-06 | 2003-11-11 | Michigan, University Of The Regents | Annexin proteins and autoantibodies as serum markers for cancer |
| AU2001253104A1 (en) * | 2000-04-03 | 2001-10-15 | Gesellschaft Fur Biotechnologische Forschung Gmbh | Methods for altering t cell and macrophage activation |
| US8614169B2 (en) * | 2001-12-04 | 2013-12-24 | Wayne State University | Neoepitope detection of disease using protein arrays |
| KR101107765B1 (ko) * | 2002-08-06 | 2012-01-25 | 싸이퍼젠 바이오시스템즈, 인코포레이티드 | 난소암의 검출을 위한 생물 마커의 용도 |
| CN101268367A (zh) * | 2005-06-24 | 2008-09-17 | 赛弗吉生物系统公司 | 卵巢癌的生物标记 |
| MX2008009592A (es) * | 2006-01-27 | 2008-09-08 | Tripath Imaging Inc | Metodos y composiciones para identificar pacientes con una probabilidad incrementada de tener cancer de ovario. |
| JP5495159B2 (ja) * | 2006-09-13 | 2014-05-21 | オンクイミューン リミテッド | 改善されたイムノアッセイ法 |
| WO2008115710A2 (en) * | 2007-03-07 | 2008-09-25 | The Johns Hopkins University | Biomarkers for cancer |
| JP5265140B2 (ja) * | 2007-06-14 | 2013-08-14 | 学校法人日本医科大学 | 卵巣癌の検出方法及び検出用キット |
| US8664358B2 (en) * | 2007-06-29 | 2014-03-04 | Vermillion, Inc. | Predictive markers for ovarian cancer |
| CA2705272C (en) * | 2007-11-13 | 2020-05-12 | Phoenix Biotechnology Inc. | Method of determining the probability of a therapeutic response in cancer chemotherapy with cardiac glycoside |
| CA2725548A1 (en) * | 2008-05-09 | 2009-11-12 | Duke University | Autoantibodies in the detection and treatment of cancer |
| WO2010070043A1 (en) * | 2008-12-19 | 2010-06-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Biomarkers for the diagnosis of renal allograft and kidney status |
| US20120004289A1 (en) * | 2009-03-06 | 2012-01-05 | The Johns Hopkins University | Annexin a11 and associated genes as biomarkers for cancer |
| CN101762699A (zh) * | 2009-06-24 | 2010-06-30 | 北京科美东雅生物技术有限公司 | 一种定量检测血液中肿瘤相关抗原125的磁性免疫层析试纸条及制备方法 |
| US20120277326A1 (en) | 2009-11-20 | 2012-11-01 | Taylor Douglas D | Biomarkers of cancer |
| JP2011257147A (ja) * | 2010-06-04 | 2011-12-22 | Nitto Boseki Co Ltd | データ収集方法、キット及び腫瘍マーカー |
| WO2013112801A1 (en) * | 2012-01-26 | 2013-08-01 | Ibc Pharmaceuticals, Inc. | Targeting interferon-lambda with antibodies potently enhances anti-tumor and anti-viral activities |
| CN102590531A (zh) * | 2012-03-24 | 2012-07-18 | 广西壮族自治区肿瘤防治研究所 | 卵巢癌相关抗原自身抗体谱液相芯片检测试剂盒及其制备方法 |
| JP5574348B2 (ja) * | 2012-05-31 | 2014-08-20 | 国立大学法人 千葉大学 | 肺サルコイドーシスおよび眼サルコイドーシスの検出マーカー及び検出キット |
| US20140179808A1 (en) * | 2012-10-23 | 2014-06-26 | Bio-Rad Laboratories, Inc. | Detection of Ovarian Carcinoma by Assay for Autoantibodies to Multiple Antigens |
| JP2016507748A (ja) | 2013-01-31 | 2016-03-10 | アリゾナ ボード オブ リージェンツ， ア ボディー コーポレイト オブ ザ ステート オブ アリゾナ， アクティング フォー アンド オン ビハーフ オブ アリゾナ ステート ユニバーシティー | 卵巣癌の早期発見のための自己抗体サイン |
-
2014
- 2014-09-18 US US15/023,155 patent/US20160291025A1/en not_active Abandoned
- 2014-09-18 CA CA2924600A patent/CA2924600A1/en not_active Abandoned
- 2014-09-18 CN CN201480063118.7A patent/CN105745543B/zh active Active
- 2014-09-18 EP EP14846089.2A patent/EP3047277B1/en active Active
- 2014-09-18 AU AU2014324080A patent/AU2014324080B2/en active Active
- 2014-09-18 JP JP2016515521A patent/JP6588893B2/ja active Active
- 2014-09-18 WO PCT/AU2014/000925 patent/WO2015039175A1/en not_active Ceased
-
2019
- 2019-01-11 US US16/245,822 patent/US11371993B2/en active Active
-
2022
- 2022-05-27 US US17/826,948 patent/US12287337B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016536568A5 (https=) | ||
| Kim et al. | Hepatocellular carcinoma: old friends and new tricks | |
| Costantini et al. | Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab | |
| Truxova et al. | Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients | |
| Wan et al. | New labyrinth microfluidic device detects circulating tumor cells expressing cancer stem cell marker and circulating tumor microemboli in hepatocellular carcinoma | |
| Vallböhmer et al. | Molecular determinants of cetuximab efficacy | |
| Kim et al. | Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival | |
| Sadeghi et al. | Serum levels of chemokines CCL4 and CCL5 in cirrhotic patients indicate the presence of hepatocellular carcinoma | |
| Wang et al. | Clinical significance of folate receptor-positive circulating tumor cells detected by ligand-targeted polymerase chain reaction in lung cancer | |
| Zhu et al. | B7-H4 expression is associated with cancer progression and predicts patient survival in human thyroid cancer | |
| Xie et al. | LARP1 predict the prognosis for early-stage and AFP-normal hepatocellular carcinoma | |
| Rubie et al. | Enhanced expression and clinical significance of CC‐chemokine MIP‐3α in hepatocellular carcinoma | |
| Kleinberg et al. | Claudin upregulation in ovarian carcinoma effusions is associated with poor survival | |
| Bahnassy et al. | Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data | |
| Duan et al. | Genetic biomarkers for hepatocellular carcinoma in the era of precision medicine | |
| Wimberger et al. | Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer | |
| Usó et al. | Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers | |
| Cha et al. | EIF4EBP1 overexpression is associated with poor survival and disease progression in patients with hepatocellular carcinoma | |
| Li et al. | CCL 20‐CCR 6 Cytokine Network Facilitate Treg Activity in Advanced Grades and Metastatic Variants of Hepatocellular Carcinoma | |
| Li et al. | Relationship between TRAF6 and deterioration of HCC: an immunohistochemical and in vitro study | |
| US20140186837A1 (en) | Methods For Diagnosing Cancer | |
| Carrasco-Torres et al. | The transmembrane transporter ABCC3 participates in liver cancer progression and is a potential biomarker | |
| Mink et al. | Evaluation of Nectin-4 and Trop-2: implications for patient outcomes and therapy in penile cancer | |
| Gunawardana et al. | Identifying novel autoantibody signatures in ovarian cancer using high-density protein microarrays | |
| Shahneh | Sensitive antibody-based CTCs detection from peripheral blood |